St. Jude Looks To Jumpstart Cardiac Surgery Business; CHF Next
This article was originally published in The Gray Sheet
Executive Summary
St. Jude expects U.S. approval of the Biocor andEpic tissue valves to shore up its declining heart valve business. Launch of the Biocor stented tissue valve is anticipated in the first half of 2004
You may also be interested in...
SJM Epic Porcine Valve Trial Signals Turnaround Of St. Jude’s Valve Business
St. Jude expects the introduction of its BioCor stented porcine tissue valve in the U.S. later this year to lead a roughly 13% turnaround of the firm's replacement heart valve business in 2003
SJM Epic Porcine Valve Trial Signals Turnaround Of St. Jude’s Valve Business
St. Jude expects the introduction of its BioCor stented porcine tissue valve in the U.S. later this year to lead a roughly 13% turnaround of the firm's replacement heart valve business in 2003
Centerpulse Rebounds 80% In Second Quarter As MDDI Index Drops 17%
Centerpulse stock surged 80.9% in the second quarter as final approval of a hip and knee class-action settlement dissipated the threat of bankruptcy, and the firm decided to divest its non-core businesses to focus on orthopedics. The issue closed at $16.55, up $7.40 for the three months